Beeld op de omslag

EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC

<p>5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Ki...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Fabio Villa (Auteur)
Formaat:	Boek
Gepubliceerd in:	Journal of Surgery and Surgical Research - Peertechz Publications, 2015-12-17.
Onderwerpen:	Perspective Study
Online toegang:	Connect to this object online.
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
door: Ken Akao, et al.
Gepubliceerd in: (2024)

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
door: Shao J, et al.
Gepubliceerd in: (2024)

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
door: S. V. Limareva
Gepubliceerd in: (2014)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
door: Xiaoyu Qian, et al.
Gepubliceerd in: (2022)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
door: Jing Zhu, et al.
Gepubliceerd in: (2021)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
door: Haosheng Zheng, et al.
Gepubliceerd in: (2024)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
door: Xiaoying Hou, et al.
Gepubliceerd in: (2018)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
door: Fouad Al Dayel
Gepubliceerd in: (2012)

Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC
door: Long Mao, et al.
Gepubliceerd in: (2020)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
door: Xi Zhong, et al.
Gepubliceerd in: (2020)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
door: Marialucia Iacovino, et al.
Gepubliceerd in: (2020)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
door: Wang Z, et al.
Gepubliceerd in: (2022)

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach
door: Elena M. Tosca, et al.
Gepubliceerd in: (2021)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
door: Dantong Sun, et al.
Gepubliceerd in: (2020)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
door: Yaming Liu, et al.
Gepubliceerd in: (2021)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
door: Connor O'Leary, et al.
Gepubliceerd in: (2020)

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
door: Wenliang Liu, et al.
Gepubliceerd in: (2022)

Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis
door: Zhihao Zhang, et al.
Gepubliceerd in: (2024)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
door: Simon Heeke, et al.
Gepubliceerd in: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
door: Qingli Cui, et al.
Gepubliceerd in: (2022)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
door: Xiaotong Song, et al.
Gepubliceerd in: (2023)

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
door: Yi-Nan Liu, et al.
Gepubliceerd in: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
door: Zhe Zhang, et al.
Gepubliceerd in: (2019)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
door: Nabil Ismaili, et al.
Gepubliceerd in: (2011)

PET/CT Based EGFR Mutation Status Classification of NSCLC Using Deep Learning Features and Radiomics Features
door: Weicheng Huang, et al.
Gepubliceerd in: (2022)

Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients
door: Wei Wu, et al.
Gepubliceerd in: (2020)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
door: Saskia Offerman, et al.
Gepubliceerd in: (2021)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
door: Ji Li, et al.
Gepubliceerd in: (2022)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
door: Yuhan Zhang, et al.
Gepubliceerd in: (2021)

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
door: Xuanhong Jin, et al.
Gepubliceerd in: (2024)

Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study
door: Ying Liu, et al.
Gepubliceerd in: (2023)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
door: Si-Yang Maggie Liu, et al.
Gepubliceerd in: (2023)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
door: Yujia Wang, et al.
Gepubliceerd in: (2021)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
door: Gang Shen, et al.
Gepubliceerd in: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
door: I. H. Bartelink, et al.
Gepubliceerd in: (2022)

Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
door: Maria Fernanda Imperio Pereira, et al.
Gepubliceerd in: (2024)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
door: Lihua Huang, et al.
Gepubliceerd in: (2015)

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
door: Xiaohan Zhou, et al.
Gepubliceerd in: (2020)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR<sup>L858R/T790M</sup> Mutations
door: Moamen A. Hassanin, et al.
Gepubliceerd in: (2022)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
door: Hao Tian, et al.
Gepubliceerd in: (2021)